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ABSTRACT
Objectives: To summarise evidence on temporary
discontinuation of medications to prevent acute kidney
injury (AKI).
Design: Systematic review and meta-analysis of
randomised and non-randomised studies.
Participants: Adults taking diuretics, ACE inhibitors
(ACEI), angiotensin receptor blockers (ARB), direct
renin inhibitors, non-steroidal anti-inflammatories,
metformin or sulfonylureas, experiencing intercurrent
illnesses, radiological or surgical procedures.
Interventions: Temporary discontinuation of any of
the medications of interest.
Primary and secondary outcome measures: Risk
of AKI. Secondary outcome measures were estimated
glomerular filtration rate and creatinine post-AKI, urea,
systolic and diastolic blood pressure, death, clinical
outcomes and biomarkers.
Results: 6 studies were included (1663 participants), 3
randomised controlled trials (RCTs) and 3 prospective
cohort studies. The mean age ranged from 65 to
73 years, and the proportion of women ranged from
31% to 52%. All studies were in hospital settings; 5
evaluated discontinuation of medication prior to
coronary angiography and 1 prior to cardiac surgery. 5
studies evaluated discontinuation of ACEI and ARBs and
1 small cohort study looked at discontinuation of non-
steroidal anti-inflammatory drugs. No studies evaluated
discontinuation of medication in the community
following an acute intercurrent illness. There was an
increased risk of AKI of around 15% in those in whom
medication was continued compared with those in
whom it was discontinued (relative risk (RR) 1.17, 95%
CI 0.99 to 1.38; 5 studies). When only results from
RCTs were pooled, the increase in risk was almost 50%
(RR 1.48, 95% CI 0.84 to 2.60; 3 RCTs), but the CI was
wider. There was no difference between groups for any
secondary outcomes.
Conclusions: There is low-quality evidence that
withdrawal of ACEI/ARBs prior to coronary angiography
and cardiac surgery may reduce the incidence of AKI.
There is no evidence of the impact of drug cessation
interventions on AKI incidence during intercurrent
illness in primary or secondary care.
Trial registration number: PROSPERO
CRD42015023210.
BACKGROUND
Acute kidney injury (AKI) is a sudden
decline in renal function, affecting up to
20% of people admitted to hospital, and is
strongly associated with increased mortality
and longer duration of hospital stay.1
Historically, recognition and treatment of
AKI has been poor.2 Recent comprehensive
initiatives in the UK have focused on impro-
ving awareness and treatment of people with
or at risk of AKI.3 It is thought that a substan-
tial proportion of AKI is triggered or exacer-
bated by prescribed medications, particularly
during times of physiological stress such as
Strengths and limitations of this study
▪ We have conducted a thorough systematic review
of the evidence from studies that have examined
interventions involving temporary discontinuation
of medications to prevent or minimise the sever-
ity, or consequences, of acute kidney injury
(AKI).
▪ This is a topic of major importance due to inter-
ventions currently being implemented to reduce
the risk of AKI throughout the UK and
internationally.
▪ Broad eligibility criteria included randomised and
non-randomised studies; primary and secondary
care; intercurrent illness or a radiological/surgical
procedure; planned and unplanned settings.
▪ The strength of the conclusion is limited by the
quality and number of studies, and absence of
evidence for important settings and classes of
medications.
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intercurrent illness, surgery or radiocontrast imaging.4
These medications include ACE inhibitors (ACEI),
angiotensin receptor blockers (ARB), diuretics, non-
steroidal anti-inﬂammatory drugs (NSAIDs). Under the
same circumstances, reduced excretion of metformin is
associated with an increased risk of lactic acidosis, while
sulfonylureas can lead to a greater incidence of hypogly-
caemia. Therefore, many clinicians, expert consensus
statements and guidelines recommend that some or all
of these medications are stopped prior to elective or
emergency procedures, or when patients become unwell
with symptoms of severe infection.5 6 Initiatives advising
patients prescribed these medications to temporarily
stop taking them when they become unwell (so-called
‘sick-day rules’) have been implemented throughout
Scotland and in local initiatives across the UK.7 However,
the evidence base to support these recommendations is
unclear, and the overall beneﬁt remains controversial.8
We conducted a systematic review and meta-analysis of
the randomised and non-randomised studies that have
examined temporary discontinuation of all or any of
these medications in patients in primary or secondary
care at risk of AKI or with newly diagnosed AKI as a
result of an intercurrent illness or a radiological/surgical
procedure (planned or unplanned).
METHODS
Systematic review methods followed guidance from the
Centre for Reviews and Dissemination (CRD)9 and the
Cochrane Collaboration;10 this review is reported accord-
ing to the PRISMA guidelines.11 The review followed a
predeﬁned published protocol.12
Study eligibility criteria
Studies, randomised and non-randomised, that evalu-
ated adults (age ≥18 years) who were taking a speciﬁed
medication and experiencing an intercurrent illness or
undergoing a radiological/surgical procedure (planned
or unplanned) in whom the medication was temporarily
discontinued for any reason were eligible for inclusion.
Medications of interest were diuretics, ACEIs, ARBs,
direct renin inhibitors, NSAIDs, metformin or sulfony-
lureas. Studies had to report a measure of kidney func-
tion (eg, incidence of AKI, estimated glomerular
ﬁltration rate (eGFR) or serum creatinine) and include
a comparator group consisting of placebo, no treatment
or usual care.
Identification and selection of studies
The following databases were searched from inception
to January 2016: Embase, MEDLINE, PsycINFO, BIOSIS
Citation Index (Web of Science), CINAHL (Cumulative
Index to Nursing and Allied Health Literature), Science
Citation Index (SCI) (Web of Science) and the Cochrane
Central Register of Controlled Trials (CENTRAL).
Supplementary searches were undertaken to identify grey
literature, completed and ongoing trials, in the following
resources: NIH ClinicalTrials.gov (http://www.clinicaltrials.
gov), metaRegister of Controlled Trials (http://www.
controlled-trials.com), WHO International Clinical Trials
Registry Platform (ICTRP) (http://www.who.int/ictrp/
en), relevant guidelines (eg, NICE in the UK) regarding
management of AKI. Reference lists of included studies
were screened. Details of the MEDLINE search strategy
are available as an online supplementary appendix.
Search results and full-text articles were independently
assessed for inclusion by two reviewers; disagreements
were resolved through consensus or referral to a third
reviewer where necessary.
Data extraction and assessment of risk of bias
We extracted data on baseline characteristics (number
of participants, participant characteristics, study settings,
study design, country, inclusion and exclusion criteria),
intervention/exposure related to stopping medication
and outcomes. The primary outcome was incidence of
AKI. Secondary outcomes included urinary biomarkers,
clinical outcomes, creatinine, eGFR, urea and blood
pressure. For dichotomous data (eg, incidence of AKI),
we extracted the number of events and participants in
each treatment group and calculated the relative risk
(RR) and 95% CI. For continuous data, we extracted
the mean and SD in each treatment group and calcu-
lated mean differences (MD) and 95% CIs.
Randomised controlled trials (RCTs) were assessed for
methodological quality using a draft version of the new
Cochrane risk of bias tool13 that includes items covering
allocation bias (random sequence generation, allocation
concealment and baseline imbalance), departures from
interventions (participant and study personnel blinding,
deviations from intended interventions and analysis in
groups to which they were randomised), attrition bias
(incomplete outcome data and robustness of results to
missing data), detection bias (blinding of outcome asses-
sors and likelihood of blinding to have inﬂuenced
results) and reporting bias (selective reporting of
outcome domain being assessed). The ROBINS-I tool
was used to assess the risk of bias in non-randomised
studies.14 It includes domains covering bias due to con-
founding, bias in the selection of participants into the
study, bias due to departures from intended interven-
tions, bias due to missing data, bias in taking measure-
ments and bias in the selection of the reported result.
Data were extracted by one reviewer using a standard
data extraction form designed for this review, and
checked by a second reviewer. The risk of bias assess-
ment was performed independently by two reviewers.
Any disagreements were resolved by consensus or refer-
ral to a third reviewer.
Data synthesis
We grouped studies by design (randomised vs non-
randomised), population (coronary angiography vs
surgery) and outcome. If there were two or more studies
assessing the same outcome, data were plotted on a
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forest plot. If data were considered statistically and clinic-
ally sufﬁciently homogeneous, then summary estimates
were produced using random effects meta-analysis.
When the same outcomes were assessed in randomised
and non-randomised studies that were considered
similar in terms of population and intervention, we
ﬁrst stratiﬁed the analysis based on study design. If
summary estimates from stratiﬁed analyses were consid-
ered sufﬁciently similar, we then produced an overall
summary estimate combining data from randomised
and non-randomised studies. For dichotomous out-
comes, we estimated summary RRs and 95% CIs; for
continuous data, we estimated summary MDs and 95%
CIs. Heterogeneity was investigated using forest plots
and the I2 statistic. Where data were considered too
heterogeneous to pool, a narrative synthesis was pro-
vided. We used GRADE to rate the overall quality of
the evidence for risk of bias, publication bias, impreci-
sion, inconsistency, indirectness and magnitude of
effect.15
RESULTS
Search results
The searches identiﬁed 4316 hits (records) of which 42
were considered potentially relevant and obtained for
full-text review (ﬁgure 1). A total of six studies (1663
participants) were included in the review: three RCTs
(522 participants)16–18 and three prospective cohort
studies (1141 participants).19–21 One study was available
only as a conference abstract and so limited details were
available for this study.21
All studies were conducted in hospital settings: ﬁve
evaluated discontinuation of medication prior to coron-
ary angiography and one prior to cardiac surgery.19 All
but one study16 restricted inclusion to patients deemed
at higher risk of AKI such as those with chronic kidney
disease (3 studies),17 18 20 diabetes (1 study)21 or a set of
criteria that deﬁned patients at high risk (1 study).19
The most commonly reported comorbidities included
diabetes, hypertension and congestive heart failure. No
studies of discontinuation of medication in the commu-
nity following an acute intercurrent illness were found.
Studies were conducted in North America, Turkey and
Israel. The mean age, where reported, ranged from 65
to 73 years and the proportion of women in the studies
ranged from 31% to 52%. Five studies evaluated discon-
tinuation of ACEI and ARBs, one small cohort study
looked at discontinuation of NSAIDs.20 The time point
at which the medication was stopped varied between
studies. Three studies reported that medication was
stopped 24 hours prior to the procedure,16 18 21 two
(including the one study of surgery) that it was stopped
on the morning of the procedure17 19 and one (the
study of NSAIDs)20 did not provide details on when
Figure 1 Flow of studies through the review process.
Whiting P, et al. BMJ Open 2017;7:e012674. doi:10.1136/bmjopen-2016-012674 3
Open Access
group.bmj.com on January 13, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
medication was stopped. The time point at which medi-
cation was started again also varied. One study stated
that medication was started up to 96 hours postproce-
dure,18 one RCT16 included two intervention arms that
compared restarting immediately postprocedure with
restarting 24 hours after the procedure and four studies
did not report on this. No studies were found that
assessed discontinuation of diuretics, metformin or sul-
fonylureas. Table 1 provides an overview of included
studies.
Risk of bias
The risk of bias assessment was performed for the
primary outcome of incidence of AKI. Two RCTs were
judged to have ‘some concerns’ regarding risk of
bias16 17 and one was rated ‘low risk of bias’.18 The two
judged at ‘some concern’ had issues with the randomisa-
tion process; all other bias domains were rated ‘low risk’.
One provided no information on the methods used to
allocate participants to the two treatment groups, the
other randomised patients by means of a coin toss but
Table 1 Details of studies included in the review
Bainey et al18
Rosenstock
et al17 Wolak et al16 Coca et al19
Goksuluk
et al21*
Weisbord
et al20
Study design RCT RCT RCT Prospective
cohort
Prospective
cohort
Prospective
cohort
Sample size 208 220 94 1017 80 44
Country Canada USA Israel North America Turkey USA
Population Coronary
angiography
Coronary
angiography
Coronary
angiography
Cardiac surgery Coronary
angiography
Coronary
angiography
Risk group CKD CKD None High risk of AKI Diabetes CKD
Mean age
(SD)
Intervention: 73
(9)
Control: 72 (8)
Intervention: 72
(10) Control: 72
(10)
65 (12) Intervention: 71
(11)
Control: 70 (12)
NR NR
Female (%) 26 52 33 31 NR NR
AKI definition Increase in SCr
≥25% or
≥0.5 mg from
baseline
Increase in SCr
>25% or 0.5 mg
from baseline
Increase in SCr
≥25% from
baseline
Increase in SCr
≥50% or
≥0.3 mg from
baseline
Increase in
SCr ≥25% or
≥0.5 mg from
baseline
Increase in
SCr ≥25%
from baseline
or ≥0.5 mg
from baseline
Comorbidities Diabetes (54%),
hypertension
(47%),
congestive heart
failure (14%),
liver cirrhosis
(1%)
Hypotension
(97%), diabetes
(55%)
Diabetes (50%),
unstable angina
(62%)
Diabetes (47%),
Hypertension
(88%),
congestive heart
failure (23%)
Diabetes
(100%)
NR
Study drug ACE/ARB ACE/ARB ACE/ARB ACE/ARB ACE/ARB NSAIDs
Intervention:
timing of hold
24 hours prior to
procedure
Day of procedure 24 hours prior
to procedure
Morning of
surgery
24 hours
before
procedure
No details
Intervention:
timing of
restart
Up to 96 hours
postprocedure
24 hours
postprocedure
(1) Immediately
afterwards; (2)
24 hours after
No details No details No details
Control Continued
throughout study
Continued
throughout study
Continued
throughout
study
Continued
throughout
study
Continued
throughout
study
Continued
throughout
study
Risk of bias Low Some: randomised
by coin toss, no
information on
allocation
concealment.
Baseline
difference
compatible with
chance
Some; no
information on
treatment
allocation,
baseline
difference
compatible with
chance
Moderate;
controlled for
confounding but
possibility of
residual
confounding
Critical; no
control for
confounding
Not assessed
*Available only as conference abstract.
ACE, angiotensin-converting enzyme inhibitors; AKI, acute kidney infection; ARB, angiotensin receptor blockers; CKD, chronic kidney
disease; NSAIDs, non-steroidal anti-inflammatory drugs; RCT, randomised controlled trial; SCr, serum creatinine.
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did not provide any information on whether allocation
was concealed. Both studies provided a reasonable over-
view of baseline characteristics, including similarities in
timings of baseline kidney function, which suggested
that any differences between groups were compatible
with chance. The risk of bias assessment highlighted
that none of the studies provided information on blind-
ing of participants, study personnel or outcome asses-
sors. However, there do not appear to have been any
departures from the intended interventions, thus knowl-
edge of the assigned intervention appears unlikely to
have inﬂuenced the study result. The outcome measure
was considered relatively objective and therefore also
unlikely to have been inﬂuenced by knowledge of treat-
ment assignment.
It was not possible to conduct a risk of bias assessment
for one of the non-randomised studies20 as this study did
not provide any numerical data and the risk of bias
assessment is performed at the result level. One of the
non-randomised studies was judged at moderate risk of
bias,19 and the other at critical risk of bias.21 The study
judged at critical risk of bias only presented crude
outcome data with no adjustment for potential con-
founding factors. It was judged at low risk of bias for all
other domains with the exception of measurement of
interventions which was judged at moderate risk of bias
as it was not clear exactly how exposure to ACEI and
ARBs was measured. The study judged at moderate risk
of bias was judged to have appropriately controlled for
confounding factors, but the guidance for the ROBINS-I
tool states that this domain can only be rated as low risk
of bias if the study is considered comparable to a well-
performed randomised trial.
Incidence of AKI
One study did not provide any numerical data on the
effect of discontinuation of medication on patient out-
comes.20 This cohort study, which assessed discontinuation
of NSAIDs, only found 3 patients out of 44 NSAID users
who were advised to discontinue their medication prior to
coronary angiography. It reported that discontinuation of
NSAID was not associated with a lower rate of AKI, but this
was limited by the small number of patients in whom
medication was discontinued.
All other studies assessed the incidence of AKI (or
contrast-induced nephropathy) in those in whom medi-
cation was stopped prior to the procedure compared
with those in whom medication was continued
(ﬁgure 2). Three studies deﬁned AKI as an increase in
creatinine of 25% or 0.5 mg/dL above baseline,17 18 21
one as an increase in creatinine of 25% above baseline16
and one used a slightly different deﬁnition of an
increase in creatinine of 50% or 0.3 mg/dL above base-
line.19 All but one suggested an increased risk of AKI in
those in whom medication was continued, but CIs were
generally wide. There was an increased risk of AKI of
around 15% in those in whom medication was contin-
ued compared with those in whom it was discontinued
(RR 1.17, 95% CI 0.99 to 1.38). Omitting the study
judged at critical risk of bias had very little effect on the
summary estimate (RR 1.16, 95% CI 0.98 to 1.37). When
only results from RCTs were pooled, the increase in risk
was almost 50% (RR 1.48, 95% CI 0.84 to 2.60; 3 RCTs),
but the CI was much wider. There was no evidence of
heterogeneity for any of these analyses (I2=0%). Based
on GRADE, the quality of the evidence was judged as
low for the analysis restricted to RCTs and very low when
non-randomised studies were included (table 2). The
evidence was downgraded due to imprecision and the
likelihood of publication bias for the analysis that
included RCTs and for study quality and publication bias
for the analysis that included non-randomised trials.
Secondary outcomes
Two studies16 17 assessed GFR and creatinine at 24 hours
postintervention (ﬁgures 3 and 4). Both suggested no
Figure 2 Forest plot showing the risk of acute kidney injury in those who stopped medication prior to procedure compared with
those who continued medication.
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difference in these measures between intervention
groups, although CIs were wide. Other outcomes
reported in single studies included urinary biomarkers
(structural AKI), clinical end points (mortality, myocar-
dial infarction, stroke, congestive heart failure, rehospita-
lisation, hypertensive treatment) and blood pressure.
Generally, there was no difference between groups in
which medication was stopped and groups in which it
was continued for any of these outcomes. Table 3 pro-
vides an overview of key outcomes; other outcomes
reported in included studies were different ways of meas-
uring these outcomes (eg, continuous rather than
dichotomous data, or change from baseline rather than
absolute value).
DISCUSSION
The results of our meta-analysis demonstrate a ∼15%
increased risk of AKI in those in whom medication was
continued compared with those in whom it was discon-
tinued (RR 1.17, 95% CI 0.99 to 1.38). When only
results from RCTs were pooled, the increase in risk was
almost 50% (RR 1.48, 95% CI 0.84 to 2.60), but the CI
was much wider. Based on the GRADE approach, the
quality of the evidence was low when restricted to RCTs
and very low when non-randomised studies were
included. There was no difference between groups in
which medication was stopped and groups in which it
was continued for any secondary outcomes, but these
were mainly assessed in single studies.
This is the ﬁrst systematic review into a topic of major
importance, as interventions of this type are currently
being implemented throughout the UK and internation-
ally, with the aim of reducing the incidence and/or
severity of AKI. We have used broad inclusion criteria in
many databases to capture randomised and non-
randomised studies, in primary and secondary care, and
for a range of AKI precipitants including intercurrent
illness and planned or emergency radiological and
surgical procedure. However, we have found that the
published evidence was sparse and has important limita-
tions. It is focused in hospital settings, mainly in patients
undergoing coronary angiography, restricted to patients
who were considered high risk for AKI and predomin-
antly evaluates discontinuation of ACEI and ARBs. The
primary deﬁnition of AKI in all studies was based on
short-term changes in serum creatinine, although deﬁni-
tions varied across studies. The deﬁnitions of AKI used
in four of the studies may have overestimated the in-
cidence of AKI compared with the currently accepted
deﬁnition of AKI, which was used in only one study.19
Since ACEIs/ARBs reduce glomerular ﬁltration rate
but preserve tubular blood ﬂow, a more marked short-
term reduction in eGFR may be associated with lower
rates of established AKI due to ongoing tubular injury.22
Indeed, the only study19 that examined alternate
biomarker-based deﬁnitions of AKI found no effect
related to drug cessation. In addition, the longer term
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impact of AKI in terms of the development of CKD or
reductions in baseline GFR was not reported. The reduc-
tion in glomerular ﬁltration rate caused by ACEI and
ARB treatment is reversible on stopping the drug.23 This
temporary rise in GFR among patients who discontinued
the drugs might have masked AKI in the studies
included here, given that AKI was deﬁned as a change
in serum creatinine from a baseline measurement that
was taken prior to drug withdrawal. Recognising the
potential for physiological rather than pathological
changes in kidney function,22 future studies will beneﬁt
from examining later clinical outcomes including incom-
plete recovery from AKI (ie, failure of serum creatinine
concentration to return to baseline), chronic kidney
disease and all-cause mortality.
To further quantify the limitations of the studies, we
conducted a formal risk of bias assessment using the
most recently developed tools. This is the ﬁrst review to
have used the ROBINS-I tool14 and the new Cochrane
tool for randomised trials.13 The majority of studies were
small and there were some concerns regarding risk of
bias in some studies, especially one of the non-
randomised studies which was judged at critical risk of
bias. Publication bias was not formally assessed in this
review because the number of studies was too small for
such an assessment to be meaningful. However, our
search strategy included a variety of routes to identify
unpublished studies and resulted in the inclusion of one
conference abstract. Despite this, we consider the likeli-
hood of publication bias in this area to be high.
Importantly, there are no studies which evaluate the
beneﬁts of stopping medication in the community fol-
lowing acute infection, and no studies that assessed dis-
continuation of diuretics that could exacerbate AKI, or
metformin and/or sulfonylureas, which may accumulate
during an episode of AKI. Only one study assessed
Figure 3 Forest plot showing the mean difference in glomerular filtration rate at 24 hours in those who stopped medication prior
to procedure compared with those who continued medication.
Figure 4 Forest plot showing the mean difference in creatinine at 24 hours in those who stopped medication prior to procedure
compared with those who continued medication.
Table 3 Summary of outcomes evaluated in single studies
Outcome Study Effect size (95% CI)
Urea (24 hours) Wolak et al16 MD=2.17 (−5.22 to 9.56)
Diastolic blood pressure (48 hours) Wolak et al16 MD=0.30 (−5.01 to 5.61)
Systolic blood pressure (48 hours) Wolak et al16 MD=−2.10 (−12.98 to 8.78)
Hypertensive treatment Wolak et al16 RR=0.17 (0.01 to 3.69)
Death Bainey et al18 RR=3.15 (0.13 to 78.17)
Myocardial infarction Bainey et al18 No events
Stroke Bainey et al18 RR=3.15 (0.13 to 78.17)
Congestive heart failure Bainey et al18 No events
Rehospitalisation Bainey et al18 RR=7.49 (0.38 to 146.89)
Interleukin 18 (IL 18) (≥120 ng/mL) Coca et al19 0.89 (0.65 to 1.23)*
Kidney injury molecule 1 (KIM 1) (≥1.15 ng/mL) Coca et al19 1.09 (0.82 to 1.44)*
Liver fatty acid binding protein (L-FABP) (≥170 ng/mL) Coca et al19 0.97 (0.73 to 1.3)*
Neutrophilgelatinase-associated lipocalin (NGAL) (≥120 ng/mL) Coca et al19 0.84 (0.60 to 1.16)*
*Adjusted for sex, age, white, CKD-EPI eGFR, diabetes, hypertension, congestive heart failure, myocardial infarction, cardiac cauterisation in
past 48 hours, electic surgery and type of surgery (CABG, valve, both).
MD, mean difference; RR, relative risk.
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discontinuation of NSAIDs and only a very small
number of patients discontinued these drugs in this
study and so it was not possible to draw conclusions
regarding the effects of discontinuing NSAIDs.
At present, a number of national organisations
provide guidance about medication cessation, as well as
many regional schemes and guidelines. The UK NICE
guidance published in 2013 recommends consideration
of temporarily stopping ACEI and ARBs in adults having
iodinated contrast agents if they have chronic kidney
disease with an eGFR <40 mL/min/1.73 m2, and in
adults, children and young people with diarrhoea, vomit-
ing or sepsis.6 In 2015, NHS Scotland and the Scottish
Patient Safety Programme initiated a more wide ranging
medication cessation intervention. Predominantly via
community pharmacists, patients are issued with
Sick-Day Rules cards, advising them to stop taking
ACEIs/ARBs, NSAIDS, diuretics and metformin when
they become unwell with vomiting or diarrhoea, and/or
fevers sweats and shaking.24 Under similar circum-
stances, guidance from the Canadian Diabetes
Association Clinical Practice Guidelines for Chronic
Kidney Disease in Diabetes recommends physicians and
patients to withhold ACEIs, ARBs, NSAIDs, diuretics,
metformin, direct renin inhibitors and sulfonylureas.25
This guidance is based on the commonly held belief
that there is an association between the use of ACEI/
ARBs, diuretics and NSAIDs and the development of
AKI, particularly during illness or other physiological
insult. The potentially strongest source of evidence, the
incidence of AKI in RCTs of ACEIs and ARBs compared
with placebo is poorly described due to variable deﬁni-
tions or absent reporting of kidney-related adverse
events.26 A number of observational studies have demon-
strated a higher risk of AKI among patients among
ACEI/ARB users also taking diuretics and/or NSAIDs
compared with those taking ACEIs/ARBs alone,27–29 or
with ACEI/ARB users compared with non-users during
acute illness or after surgery.30 31 As with all observa-
tional evidence, these studies carry an inherent risk of
associations being due to bias and confounding, particu-
larly confounding by indication, in which patients at
higher risk of AKI are more likely to be treated with the
drugs of interest, making a direct causal effect
uncertain.
Only one of the studies17 considered in this review was
available at the time of development of the NICE guid-
ance for AKI.6 The guideline development group
discuss explicitly the difﬁculty of issuing guidance
regarding medication cessation (for ACEIs/ARBs only),
despite limited evidence.6 They felt that the available
evidence for discontinuation was weak but that the ‘con-
tinuing use of ACEIs/ARBs [during acute illness or
exposure to iodinated contrast agents] is clearly asso-
ciated with AKI. In contrast, the temporary suspension
of ACEIs/ARBs for a short period seems unlikely to
greatly increase the risk of cardiovascular events’.
Subsequent evidence regarding the safety of community
medication cessation interventions has come from an
ongoing evaluation of hospital admissions following
introduction of the NHS Scotland scheme, which has
shown a stabilisation or fall in hospital admissions with
AKI.24 However, a concurrent fall in heart failure admis-
sions (which might have been expected to increase as a
consequence of discontinuation of ACEIs or ARBs
among patients previously stabilised on these drugs for
treatment of heart failure) suggest a secular trend in
hospital admissions unrelated to the introduction of the
intervention, and interpretation is also limited by the
absence of a control population. There remains ongoing
disagreement about how the general evidence base
should be interpreted to consider the balance of risks
and beneﬁts of drug-cessation interventions, particularly
during acute illness.8
This systematic review includes ﬁve additional studies
published since the NICE guidance on AKI. Our results
show low-quality evidence that withdrawal of ACEI/ARBs
and NSAIDs prior to coronary angiography and cardiac
surgery may reduce the incidence of AKI. However, the
quality, power and limited scope of these studies reduce
the emphasis that can be placed on this ﬁnding and
have not substantially clariﬁed the evidence base. There
is no published evidence of the impact of drug cessation
interventions on AKI incidence during intercurrent
illness in primary or secondary care, of other included
medications (NSAIDs, diuretics, sulfonylureas, metfor-
min) or of combinations of medications. We also found
no evidence of ongoing studies of interventions on any
of these topics.
The current widespread promotion of ‘sick-day guid-
ance’ incurs ﬁnancial and opportunity costs. While the
public health impact of sick-day guidance can be evalu-
ated through the novel data ﬂows recently established by
NHS England and the UK Renal Registry,3more formal
controlled evaluation in the form of stepped wedge or
cluster randomised trials could be applied to ensure we
achieve maximal overall public health beneﬁt.
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